Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2017

View Archived Issues

Skinvisible and Quoin Pharmaceuticals enter non-binding term sheet for proposed merger

HEALOS phase III study of AM-111 does not meet the primary efficacy endpoint

Positive topline data reported from Abide Therapeutics' phase Ib study of ABX-1431

Aptevo Therapeutics to conduct phase II study of otlertuzumab

Preclinical antidepressant effects seen with sestrin-2 modulator NV-5138

C-458 shows promising results for Alzheimer's disease treatment

G1 Therapeutics enters clinical trial collaboration with AstraZeneca

Viking Therapeutics phase II study of VK-5211 meets primary endpoint

PhaseBio Pharmaceuticals obtains license to ticagrelor reversal agent

Synpromics and UCL enter Parkinson's disease gene therapy collaboration

Gilead and X-Chem form drug discovery collaboration

Phase III JAVELIN Gastric 300 trial of avelumab does not meet primary endpoint

FDA grants priority review to mogamulizumab BLA for CTCL

Takeda Pharmaceutical commences phase I study of Zika vaccine candidate TAK-426

GSK seeks U.S. approval for tafenoquine for prevention of relapse of P. vivax malaria

Hepatera and MYR report interim results from phase IIb study of Myrcludex B

Charles River and Enyo collaborate to identify mode of action of EYP002 series

Phase I data support inclusion of adolescents in Ovid's phase II trial of OV-101

Researchers present new DT-induced PAH animal model

Phase I studies reveal signs of antiparkinsonian efficacy of PF-06649751

Abide Therapeutics describes novel monoglyceride lipase/monoacylglycerol lipase ABHD6 inhibitors

New anti-tenascin-C antibodies synthesized at Roche

A*STAR presents novel anti-CTLA-4 antibodies

Novel Staphylococcus epidermidis autoinducing peptide analogues discovered at WARF

TNB-383B, a novel bispecific antibody candidate with efficacy in multiple myeloma models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...